Luis Manrique, MD
Infectious Disease · Winfield, ILNPI 1245257062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. EMD Serono, Inc. accounts for 74.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $259 and has fallen 64.1% since, to $93 in 2024.
Across 8 payments — averaging $61.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$365
- Sanofi$80
- AbbVie$18
- Shionogi Inc$13
- Melinta Therapeutics, LLC$12
Across 18 payments — averaging $23,848 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$398K
- Gilead$29K
- Octapharma USA, Inc.$2K
What the payments were for
- Food & beverage$46395%
- Education$255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 4 | $365 |
| Sanofi | 1 | $80 |
| AbbVie | 1 | $18 |
| Shionogi Inc | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$226
How this compares
$488 in reported general payments places this provider in the 65th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 32 | $131,078 |
| Etravirine | 14 | $16,876 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 15 | $8,551 |
| Fosfomycin Tromethamine | 30 | $6,081 |
| Meropenem | 28 | $5,812 |
| Albendazole | 15 | $4,753 |
| Vancomycin Hcl | 31 | $1,465 |
| Ritonavir | 12 | $1,380 |
| CeftriaxoneCeftriaxone Sodium | 15 | $1,205 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $1,126 |
| Doxycycline Monohydrate | 15 | $1,071 |
| CefuroximeCefuroxime Axetil | 17 | $968 |
| Cefazolin Sodium | 13 | $586 |
| Cephalexin | 48 | $512 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $354 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Winfield
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.